We are the pioneers in diagnostic testing for breast and other hereditary cancers. Today, the 35-gene Myriad myRisk® Hereditary Cancer test is keeping us at the forefront of scientific innovation in molecular diagnostics.
Recent evidence suggests up to 15% of breast cancers may be associated with a genetic predisposition. By screening for genes such as BRCA1 and BRCA2 we can determine if an individual may have a significantly increased chance to develop cancer in the future. Individuals who carry a mutation in either the BRCA1 or BRCA2 gene have a condition called Hereditary Breast and Ovarian Cancer (HBOC) syndrome, which is associated with an 87 percent risk of developing breast cancer by age 70. Mutation carriers who have already been diagnosed with cancer also have a significantly increased risk of developing a second cancer. By offering Myriad’s MyRisk genetic test we can identify patients with who have mutations in BRCA1, BRCA2, and many other genes.
A patient’s personal or family history indicates that he/she may be at increased risk to have a genetic mutation that increases their risk of cancer. Genetic testing provides the most accurate means of assessing cancer risk. Knowing the potential risk can help you make better, more informed decisions about your health, before the onset of cancer or before a second cancer has developed.
Genetic testing for hereditary breast and ovarian cancer with the Myriad myRisk Hereditary Cancer panel should be considered if:*
If hereditary cancer genetic testing confirms the presence of a BRCA1 or or BRCA2 mutation or another gene associated with breast cancer risk, the following medical management options may help to reduce your patient’s breast cancer risk and may either prevent or delay the onset of cancer or detect cancer at an earlier, more treatable stage, when outcomes are better:
Hereditary cancer gene panel testing results can assist you in developing personalized medical management plans that can help you:
*Assessment criteria are based on individual medical society guidelines.
**HBOC-associated cancers are breast (including DCIS), ovarian, prostate and pancreatic.
Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.